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Abstract 
Objectives: The ways of pharmacological correction of cardiovascular complications in 
the syndrome of the systemic inflammatory response (SIRS) are not fully developed. 
Goal: Determination of statins‘ new pharmacological effects and its combination with 
endothelioprotectors in the SIRS correction.  
Materals and Methods: In experiments on mice, rats and rabbits, the anti-
inflammatory, cardioprotective and endothelioprotective effects of statins and 
endothelioprotectors were explored. The modeling of endotoxin-induced endothelial 
dysfunction (EIED) was created by infecting rats with Staphylococcus aureus (strain 
13407), subcutaneously (60 billion microbial bodies). To determine the activity of the 
inflammatory process, the indices of the C-reactive protein used. The involvement of 
the cytokine link of inflammation was assessed according to the plasma levels of TNF-α 
and IL-6. Modeling of L-NAME-induced pathology and further evaluation of 
endothelial and endothelium-independent vascular reactions were carried through 
according to a standard protocol. 
Results: Simvastatin (9, 19, 35 mg/kg), atorvastatin (5, 9, 19 mg/kg), rosuvastatin (9, 
19, 35 mg/kg) and nanoparticulated rosuvastatin (3, 6.3 and 11.6 mg/kg) proved a dose-
dependent antiexudative effect on the model of formalin paw edema in mice. Similarly, 
the anti-inflammatory effect is evident in the exudative model on rabbits. The greatest 
effectiveness was demonstrated by rosuvastatin and its nanoparticularized form. 
Simvastatin 8.5 mg/kg, atorvastatin 4.3 mg/kg, rosuvastatin 8.5 mg/kg, and 
nanoparticulated rosuvastatin 11.6 mg/kg demonstrate a cardioprotective effect in the 
coronary-occlusive modeling of infarction in rats. In the process of cardioprotective 
effects‘ implementation the mechanisms of pharmacological preconditioning has 
significant importance. It was proved by the removal of effects with K + -ATP-as 
channels blockade with glibenclamide (5 mg/kg) and iNOS blockade with 
aminoguanidine (40 mg/kg). 
The use of inhibitors HMG-CoA reductase of simvastatin (2.2, 4.3 and 8.5 mg/kg), 
atorvastatin (1.1, 2.2 and 4.3 mg/kg), rosuvastatin (2.2, 4 , 3 and 8.5 mg/kg) and 
nanoparticulated rosuvastatin (3, 6.3 and 11.6 mg/kg) on the background of endotoxin-
induced pathology modeling leads to the development of a dose-dependent 
endothelioprotective effect, which is expressed in normalization of coefficient of 
endothelial dysfunction (CED), to prevention of adrenoreceptivity increase and to the 
exhaustion of the myocardial reserve, as well as to the normalization of biochemical 
markers of inflammation (C-reactive protein) and the level of pro-inflammatory  
cytokines. At the same time, positive dynamics of the final products of NO and eNOS 
expression was defined. 
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Applying of monotherapy with donator NO L-arginine (70 and 200 mg/kg), a 
nonselective inhibitor of arginase BEC (5 and 10 mg/kg), a selective inhibitor of 
arginase-2 arginasine (1 and 3 mg/kg) and recombinant darbepoetin (50 and 500 μg/kg) 
in the modeling of endothelial dysfunction, has revealed their high activity, expressed in 
preventing the increase in CED, adrenoreactivity, preservation of the myocardial reserve 
and normalization of the values of biochemical markers (Total NO, eNOS expression,  
C-reactive protein, IL-6, TNF). Herewith, the drugs had a dose-dependent effect and 
were approximately equally effective. 
A vector analysis of the additive effects of the combined use of inhibitors of HMG-CoA 
reductase, simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin with 
L-arginine, inhibitors of arginase – BEC and arginasine, as well as darbepoetin 
demostrated that, with endotoxin-induced pathology, the highest probabilistic 
percentage of addiction was found in combination of rosuvastatin with arginasine (3 
mg/kg) and darbepoetin (500 μg/kg), relatively, 31.9 ± 2.8 and 30.2 ± 2.9%.  
Discussion: The inhibitors of HMG-CoA reductase have demonstrated cardioprotective 
(decrease of adrenoreactivity and depletion of myocardial reserve, normalization of 
blood pressure) and endothelioprotective (amplification of eNOS expression, increase of 
NO) the attributes, which manifested itself as well as in monotherapy and in 
combination with some endothelioprotectors (L-arginine, arginasine, BEС, darbepoetin) 
in varying degrees. 
Keywords: endothelial dysfunction, nitric oxide, statins, endothelioprotectors, systemic 
inflammatory response syndrome. 
 
Introduction 
Inflammation is a distinctly coordinated 
systemic reaction of the body, focused on 
eliminating of the damaging agent. However, 
rather often an inflammatory reaction causes 
more damage to the body than the etiologic 
factor that had induced it [1]. More than 100 
years ago, William Osler in his reflections 
about sepsis had correctly suggested that, 
except some rare cases, the cause of death in a 
septic process is not an infection, but the body's 
response to it. A contemporary 
pathophysiology explains this phenomenon 
through the concept of a systemic inflammatory 
reaction (SIRS), considered as a response of the 
organism to various flogogenic effects of 
infectious and non-infectious origin [2]. The 
scientific researches of the last decade led to 
the formation of an integral picture describing 
SIRS through a cascade of neurohumoral 
reactions, formed by complex mediator and 
cytokine nets. Describing the pathogenesis of 
systemic inflammation, several main stages can 
be identified: 1) presentation of 
lipopolysaccharide on the surface of the 
endothelium, massive stimulation of the 
pattern-recognition cells receptors of immune 
and reticuloendothelial systems; 2) the release 
of inflammatory mediators (bradykinin, 
prostaglandins, histamine, proinflammatory 
cytokines) and the change of the expression 
molecules profile of intercellular interactions 
(integrins, selectins) followed by leukocyte 
adhesion and iNOS activation; 3) the growth of 
cytotoxic NO concentrations with the formation 
of active forms of nitrogen, the breakdown of 
intercellular contacts and the oxidation of LDL, 
the change of the antithrombotic properties of 
the endothelium to prothrombotic and the 
migration of leukocytes through the wall of 
micro vessels with further infiltration of tissues 
and the absorption of oxidized LDL;  
4) hyperproduction of ROS, vasodilation, 
microthrombosis and systemic manifestations 
of SIRS; 5) death due to the gradual 
decompensation of life-support processes at the 
systemic level or recovery [3]. It is easy to see 
that one of the central participants of this 
continuum is the endothelium, which does not 
just produce the widest spectrum of humoral 
factors, but also realizes the processes of 
exudation, thrombosis and hemodynamics 
control. The more interesting fact is that the 
majority of patients who underwent abdominal 
catastrophes [4, 5, 6, 7], sepsis [8, 9, 10] and 
other infectious nosology associated with SIRS 
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[8, 11, 12] after regression of the pathological 
process on various terms are developing 
complications associated with endothelial
dysfunction (atherosclerotic vascular lesions, 
myocardial infarction, cerebral stroke) [13, 14] 
(Fig. 1). 
 
 
 
Fig. 1. Pathogenesis of vascular wall damage in SIRS. 
Note: Pathogenesis of the formation of an inflammatory injury of the vascular wall with subsequent 
atherogenesis and thrombus formation. LPS binds to the Toll-receptors of the endothelial cell, 
enhancing the release of pro-inflammatory cytokines and the expression of adhesion receptors, to 
which leukocytes are attracted by β- integrins followed by iNOS activation and massive NO release, 
the latter forming the peroxynitrite (ONOO-) and nitrosyl chloride (NOOCl) radicals, damaging 
cellular structures and dissociating eNOS. As a result, intercellular contacts are destroying; oxidized 
by free radicals of LDL induce the cascade of reactions, leading to an even greater dissociation of 
eNOS. Disturbance of cells structures contributes to increased vascular permeability and migration of 
leukocytes, their absorption of oxidized LDL and formation of foamy cells – harbingers of 
atherosclerotic plaques. The destruction of the endothelium and exposure of the subendothelial layer 
creates conditions for the activation and aggregation of thrombocytes with thrombosis 
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At the same time, with the coherence of the 
pathogenetic regimens and the inclusion of 
multiple factors (VEGF, sFlt-1, autoantibody of 
receptor angiotensin II (type 1) (AT1-AA), 
cytokines (tumor necrosis factor (TNF) -α), 
endothelin, active forms of oxygen (ROS), 
thromboxane, 20-hydroxyicosatetraenoic acid 
(20-HETE), increased sensitivity to angiotensin 
II, etc.), the inadequacy of pharmacotherapeutic 
strategies pointed to correction of endothelial 
dysfunction in acute systemic inflammation is 
obvious. Besides, we can suppose the 
mechanisms underlying the ischemic 
preconditioning may play a role in pathogenetic 
approaches to the correction of multiple organ 
failure in endotoxin-induced pathology, 
including myocardium, brain, kidney, retina 
[15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]. 
From this regard the inhibitors of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) – 
reductase are very perspective. Being the gold 
standard of lipid-lowering therapy [26, 27, 28, 
29, 30, 31, 32, 33, 34], statins continue to 
attract the attention of researchers because of  
their inherent pleiotropic effects [35, 36, 37], 
including cardioprotective [38, 39] anti-
inflammatory [40, 41] and endothelioprotective 
[42]. These effects do not depend upon 
cholesterol decreasing, but caused by the main 
mechanism of action – inhibition of HMG-CoA 
reductase. Tit is concerned with the fact that a 
number of intermediate products in the chain of 
cholesterol synthesis, such as farnesyl 
pyrophosphate and geranylgeranil 
pyrophosphate, have pro-inflammatory, 
prooxidant and several other negative attributes 
are realizing through the activation of 
secondary mediators Ras Rac1, Rho [43].  
It is shown that activation of Rho is 
associated with inhibition of eNOS, and an 
increase of leukocytes migration through the 
vascular wall. The activation of Ras is 
connected with the synthesis initiation of pro-
inflammatory cytokines, while the activation of 
Rac1 is connected with an increase in 
mitochondrial NADPH oxidase activity, what 
contributes to the oxidative stress development 
of [44]. 
Numerous researches with the use of 
different models had convincingly 
demonstrated that statins possess anti-apoptotic 
activity and reduce the level of 
proinflammatory cytokines, chemokines and 
adhesion molecules. Antithrombotic effects of 
statins can improve the coagulopathy caused by 
sepsis. By influencing on the modification of 
proteins, they prevent the presentation of the 
antigen by the endothelial cell and recognition 
by the immune cells. The ability of statins to 
increase eNOS expression and reduce iNOS 
concentration has been also demonstrated. It 
has a great importance both for limiting the 
extent of damage in SIRS and for limiting the 
extent of endotoxin-induced endothelial 
dysfunction as well [45].  
On the other hand, endothelium is a classic 
target of such pharmacological agents as L-
arginine, BEC and darbepoetin. Theirs mono- 
and combination therapy has been proved as a 
successful in treating of a wide range of 
cardiovascular pathologies [46]. 
From this aspect, the pharmacological 
target "ADMA-eNOS", which was the research 
object of Kursk's and after of Belgorod‘s 
pharmacologists [47, 48, 49, 50, 51, 52], and 
also of their colleagues from Volgograd, has a 
definite interest [53, 54, 55, 56]. 
Methylated analogs of L-arginine – 
asymmetric dimethylarginine (ADMA) and 
monomethylarginine (L-NMMA) – are 
endogenous inhibitors of endothelial nitric 
oxide synthase (eNOS). In recent years, it has 
been found that ADMA concentrations in 
endotoxin shock are increasing and elevated 
concentrations of ADMA are one of the key 
risk factors of the cardiovascular nosological 
continuum [57]. 
Taking into consideration the fact that one 
of the main pathogenetic aspects of SIRS 
development is the imbalance between the 
inducible and endothelial isoforms of NOS 
[58], pharmacotherapeutic correction of 
endothelial dysfunction in systemic 
inflammation should be aimed at overcoming 
the internal inhibition of eNOS, including 
ADMA. 
The researches on overcoming the 
inhibitory effect of ADMA by the introduction 
of L-arginine [59], tetrahydrobiopterin [60], a 
nonselective inhibitor of arginase L-norvaline 
[61], selective inhibitors of arginase-2 
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arginasine [62] and others  has got a 
considerable development nowadays. 
Based on this point of view, HMG-CoA 
reductase inhibitors and endothelioprotectors 
can potentially have complementary effects in 
prevention and treatment of endothelial 
dysfunction and other pathological conditions 
associated with systemic inflammation.  
Accordingly, there are significant 
theoretical prerequisites for the use of drugs 
aimed at correcting endothelial function (in 
particular, statins and endothelioprotectors) in 
complex treatment and in prevention of SIRS. 
Hereby one of the main elements of the 
proposed pharmacotherapeutic strategies is 
statins. This group of drugs is in demand all 
over the world and some of them are so-called 
blockbusters with sales volumes of more than 
5-7 billion dollars per year in financial 
equivalent. From the chemical point of view, 
statins are represented by 8 international non-
proprietary names, different in lipo- and 
hydrophilicity and also in a number of 
pharmacokinetic and toxicological indicators. 
Simvastatin and atorvastatin are the most 
prevalent. But rosuvastatin is up-to-date.  
Objective: to study the effectiveness of 
pharmacological correction of endotoxin-
induced pathology by statins using 
(simvastatin, atorvastatin, rosuvastatin, 
nanoparticulated rosuvastatin) and their 
combinations with L-arginine, BEC arginase 
inhibitors and selective inhibitor of arginase-2 
arginasine, and also by recombinant 
darbepoetin.  
 
Materials and Methods  
The experiments were made on healthy 
matured rats of the Wistar line, weighing 180-
250 g; laboratory mice weighing 18-22 g; and 
also rabbits weighing 2-2.5 kg. In the 
experiments, we used animals that passed 
through the quarantine regime of the Kursk 
State Medical University vivarium and did not 
have any external signs of any diseases. All 
animals were kept in the same conditions, on a 
normal diet. For the statistically reliable results, 
the groups were formed from 18-20 animals. 
The animals that were included into a control 
and into an experimental group were of the 
same age and came from the Stolbovaya cattery 
of the Russian Academy of Medical Sciences. 
The spread in groups according to the initial 
mass did not exceed -10%. All experiments 
were carried out at the same time of the day, 
from 8 a.m to 12 a.m, in accordance with the 
principles set forth in the Convention for the 
Protection of Vertebrates used for experimental 
and other purposes (Strasbourg, France, 1986) 
and in accordance with the rules of laboratory 
practice in the Russian Federation (Order of the 
Ministry of Health of the Russian Federation 
No. 267 of June 19, 2003). 
The investigation of the anti-
inflammatory effect on the model of 
formalin edema of mice: The experiments 
were made on laboratory mice weighing 18-22 
g. The anti-inflammatory effect was evaluated 
in conditions of acute aseptic inflammation of 
the formalin-induced mice, according to the 
degree of inhibition of the edema of the foot 
increasing by the drugs in comparison with the 
control group of untreated animals. Exudative 
edema was induced by subcutaneous injection 
into the right rear foot of mice with 0.02 ml of 
a 2% aqueous solution of formalin. The mass of 
the foot was measured in 4 hours (at the peak 
of the edema) after injection of phlogistics on 
electronic scales with an accuracy of 1 mg; as a 
control measure the left paw of the same 
animal was used, which was injected with an 
equal volume of isotonic NaCl solution in 
parallel with the injection of the flogogenic 
agent. The inhibitory effect was calculated by 
the formula:  
Mc
MeMc
Eing
%100)(
 , 
where Eing  – the inhibitory effect, Me  and 
Mc – the average increase of the edematous 
foot mass in the control and experimental 
groups.  
The anti-inflammatory effect 
investigation according to I.A. Oivin 
method. The experiments were made out on 
laboratory rabbits (3 rabbits in each group) 
weighing 2-2.5 kg. To investigate the anti-
inflammatory activity of the drugs using the 
Oivin method, the rabbits were fixed; 
previously hair has been cut on the abdominal 
skin (13 x 5 cm piece). Tripanum coeruleum 
(permeability indicator) was injected into the 
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edge vein of the ear in the form of a 1% 
solution on a 0.9% solution of sodium chloride 
at a rate of 2 ml per 1 kg of animal weight. 
Then 6-12 drops of o-xylene were applied to 
the area of the abdominal skin. The indicator of 
the permeability of capillaries was the time of 
appearance of blue-stained spots on the skin 
and their diameter. By the difference in the 
time of appearance of the spots and their 
diameter before and after the injection of the 
drug, it was judged on its effect on the 
permeability of capillaries. 
A simulating model of coronary-
occlusive myocardial infarction in rats and 
evaluation of the magnitude of the necrosis 
zone. 
The experiments were made on male 
Wistar rats of 200-250 g. The drug was injected 
intraperitoneally 1 time per day and 30 minutes 
before modeling myocardial infarction (MI). 
MI was reproduced on anesthetized animals by 
bandaging the descending branch of the left 
coronary artery on the lower edge of the left 
atrial appendage level, then the wound was 
layer-by-layer sutured. 
On the 4
th
 day, the animal was killed, the 
heart was removed, and crossed sections were 
made every 4-6 mm, and then incubated in a 
1% solution of triphenyltetrazolium of blue in 
phosphate buffer pH 7.4 for 15 minutes at  
37 ° C. This method makes it possible to 
visualize clearly the necrosis zone (not colored) 
for further examination. 
Quantitative analysis and calculation of the 
area of necrotic tissue was carried out by means 
of the graphic editor Adobe Photoshop CS5 
[63]. 
To analyze the participation of K⁺-ATPase 
channels and iNOS in the realization of the 
protective effects of pharmacological 
preparations, glibenclamide [64, 65] and 
aminoguanidine [66, 67] were used.  
A simulating model of endotoxin-
induced endothelial dysfunction. 
In the modeling of endotoxin-induced 
endothelial dysfunction, the rats were infected 
with Staphylococcus aureus (strain 13407), 
subcutaneously with 60 billion microbial 
bodies, with followed by (after 24 hours) 
sensitization of the laboratory animal (0.1 ml of 
staphylococcal anatoxin subcutaneously), 
followed by generalization of the infectious 
agent by daily injection place massage. Further, 
a compression, pneumatic massage of the 
injection place was performed daily during 10 
minutes [68].  
To determine the activity of the 
inflammatory process, the indices of the C-
reactive protein were used. The involvement of 
the cytokine link of inflammation was 
estimated according to the plasma content of 
TNF-α and IL-6, determined by immunoassay 
methods using the Alfa-TNF-α-IFA-Best 
reagents kits; "IL-6-IFA-Best" [69, 70, 71].  
Modeling of L-NAME-induced gestosis 
and estimation of endothelium-dependent 
and endothelium-independent vascular 
reactions (M.V. Pokrovsky and co- auths., 
2006). 
N-nitro-L-arginine methyl ether (L-
NAME) was injected to males daily, once a 
day, intraperitoneally at a dose of 25 mg/kg. On 
the 8
th
 day from the beginning of the 
experiment, an L-NAME-induced and 
hyperhomocysteine-induced endothelial 
dysfunction a catheter was put in (under 
anesthesia bychloral hydrate 300 mg/kg) into 
the left carotid artery to record hemodynamic 
parameters. Hemodynamic parameters: systolic 
blood pressure (SBP), diastolic blood pressure 
(DBP) and heart rate (HR) were measured 
continuously, using the Biopac hardware 
complex (USA) and the computer program 
"Acqknowledge 3.8.1". Bolus injection of 
pharmacological agents was made into the right 
femoral vein. The following functional tests 
were performed: intravenous acetylcholine (40 
μg/kg) [72] and sodium nitroprusside (30 
μg/kg) [73]. 
A study of myocardial contractility after 
pathology modeling was made in narcotized 
rats on controlled respiration. The left ventricle 
cavity was probed with a needle through the 
apex of the heart and by means of the hardware 
complex "Biopac" (USA), the computer 
program "Acqknowledge 3.8.1", the parameters 
of cardiohemodynamics (left ventricular 
pressure, maximum reduction rate (+ dp / dt 
max), maximum relaxation rate (-dp / dt max), 
heart rate (heart rate) were registered.  
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To estimate the functional capabilities of 
the myocardium in animals, burthen tests were 
performed in the following sequence:  
1. Adrenoreactivity test – intravenous one-
stage injection of an adrenaline hydrochloride 
solution 1*10
-5
 mol/l, calculated on the basis of 
0.1 ml per 100 g of body weight [74]. 
2. Resistance test – clamping of the 
ascending aorta by 30 sec. [75].  
Biochemical markers of endothelial 
dysfunction. 
A modification of the method for the 
determination of stable metabolites of NO was 
used; it allows one-step quantitative 
determination of total nitrates and nitrites after 
deproteinization of blood serum [76]. The 
principle of the method is in simultaneous 
reduction of nitrates to nitrites in the presence 
of chloride bath tubing and the reaction of 
diazotization followed by the development of 
color. 
The level of expression of endothelial nitric 
oxide synthase (e-NOS) was determined in a cell 
lysate by using the Hendrickson method [77]. 
Detection of the eNOS band was carried out by 
the method of enhanced chemiluminescence 
(ECL). 
Justification of doses and the experiment 
design:  
In this research, the study of endothelial 
and cardioprotective activity of statins in doses 
was made; anti-inflammatory effects were 
detected before [78, 79]. In chronic 
experiments in the modeling of EIED and L-
NAME-induced endothelial dysfunction, drugs 
were injected at appropriate doses once a day 
intraperitoneally or intragastrically for 7 days 
30 minutes after  
L-NAME injection. 
 
Table 1 
The correlation of doses of inhibitors of HMG-CoA reductase simvastatin, atorvastatin, 
rosuvastatin for humans and experimental animals (rabbits, rats and mice) [80] 
 
Drug 
Human doze, 
mg 
Rabbit 
mg/kg 
Rat 
mg/kg 
Mouse 
mg/kg 
Simvastatin  5 
10 
20 
2.2 
4.3 
8.5 
4.3 
8.6 
17.2 
9 
19 
35 
Atorvastatin 2.5 
5 
10 
1.1 
2.2 
4.3 
2.2 
4.3 
8.6 
5 
9 
19 
Rosuvastatin 5 
10 
20 
2.2 
4.3 
8.5 
4.3 
8.6 
17.2 
9 
19 
35 
Nano-rosuvastatin - 
- 
- 
0.73 
1.43 
2.83 
3 
6.3 
11.6 
6.2 
13.9 
23.6 
 
Simvastatin "Zokor"
®
 tablets, film-coated 
20 mg, 28 pcs. packing contour mesh 14, 
cardboard pack 2 code EAN: 4601969006711 
No. P N013094 / 01, 2011-10-24 Merck 
Sharp & Dohme B.V. (Netherlands). 
Atorvastatin "Lipitor" Tablets of round 
form 10, 20, 40 mg in a shell in a blister in 
cardboard bundle No. 30. Manufacturer: 
Gedeke / Parke-Davis, Pfizer, Inc. (Germany). 
Rosuvastatin "Crestor" Crestor® tablets, 
film-coated 10 mg, 7 pcs. blister 7, a pack of 
cardboard 1 code EAN: 7321838721251 No. П 
N015644 / 01, 2009-03-24 AstraZeneca UK 
Ltd. (United Kingdom). 
Nanoparticulated-rosuvastatin, substance. 
Manufactured in V.N. Orekhovich Research 
Institute of Biomedical Chemistry (Russian 
Federation).  
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Glibenclamide Maninil® 5 tablets 5 mg, 
120 pcs. a bottle (bottle) 120, a pack of 
cardboard 1 code EAN: 4013054000922 No. П 
N011519 / 01, 2012-03-07 Berlin-Chemie AG / 
Menarini Group (Germany). 
Aminoguanidine Aminoguanidine 
hydrochloride (Sigma-Aldrich) CAS Number 
1937-19-5 Linear Formula NH2 NHC (= NH) 
NH2 • HCl9. 
A study of L-arginine produced by 
EUROBIOPHARM GmgH (Hamburg) was 
made by intraperitoneal injection at doses of 70 
and 200 mg/kg/day. This dose is selected in 
accordance with the literature data, where the 
dosage range for the L-arginine activity is in 
the range of 30 mg/kg to 200 mg/kg [81].  
A nonselective inhibitor of arginase – S- 
(2-boro-ethyl) -L-cysteine (BEC), (WIRUD 
GmgH, Hamburg) was injected at a dose of  
10 mg/kg/day. According to modern 
researchers, BEC is able to inhibit arginase [81] 
exactly from this dosage.  
Recombinant darbepoetin ―Aranesp‖ 
injection solution 0.3 mg, 1 unit syringes 0.6 
ml Amgen Europe B.V. (Netherlands). It was 
injected intraperitoneally at doses of 50 and  
500 μg/kg for 7 days. (K.M. Reznikov, co-
authors, 2017) [83] 
Selective inhibitor of arginase-2 arginasine 
(laboratory code ZB49-0010) synthesized in 
TVC "ChemRar" was administered 
intraperitoneally at a dose of 1-3 mg/kg/day. 
Design of the experiment on the study of 
cardio and endothelioprotective activity of 
inhibitors of HMG-Co-A-reductase 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin in combination 
with L-arginine, BEC. Arginasine and 
darbepoietin consists of the following blocks: 
1. Control group. 
2. Simulation of EIED or L-NAME-
induced deficiency of nitric oxide. 
3. Estimation of endothelial and 
cardioprotective effects of inhibitors of HMG-
Co-A-reductase of simvastatin and L-arginine, 
BEC, arginasine and darbepoetin.  
4. Appraisal of the effectiveness of 
endothelial and cardioprotective effects of the 
combined use of HMG-CoA reductase 
inhibitors and L-arginine, BEC, arginasine and 
darbepoetin.  
The protocol consists of the following 
sections:   
1. Simulation of EIED and or L-NAME-
induced deficiency of nitric oxide and its 
correction with the help of inhibitors of HMG-
CoA reductase and L-arginine, BEC, arginasine 
and darbepoetin.  
2. On the 8th day in the conditions of 
etaminal-sodium anesthesia, the appraisal of 
endothelium-dependent and endothelium-
independent reactions of arterial pressure on 
intravenous one-stage administration of 
acetylcholine and sodium nitroprusside.  
3. Connection of the animal to the artificial 
ventilation of the lungs left ventricular 
catheterization, registration of the LDL, + dp / 
dt, -dp / dt, HR, IFS. Stress tests for assess the 
functional reserves of myocardial contractility.  
4. Removal of the animal from the 
experiment and taking blood from the thoracic 
aorta for biochemical studies.   
5. Taking samples of myocardial tissue for 
morphological examination and determination 
of the diameter of cardiomyocytes. 
Statistical processing of the research 
results  
For graded data, the normality of the 
distribution was determined by using the 
Shapiro-Wilk criteria. In the case of normal 
distribution, the significance of the differences 
was assessed using a one-dimensional analysis 
of variance or dispersion analysis for repeated 
measurements, followed by the Dunnet method 
of multiple comparisons. In a case if there 
wasn‘t normal distribution, a nonparametric 
analogue of the Friedman dispersion analysis 
was used with subsequent processing by the 
method of multiple comparisons according to 
Newman-Keils or Dunnet. The non-parametric 
Wilcoxon test for coupled samples and Mana-
Whitney were also used [84, 85]. 
The alternative data was worked on with 
the help of Fisher's exact probability method 
and the χ2 criterion. To estimate the correlation 
between anti-inflammatory activity and 
endothelioprotection, the Pearson correlation 
coefficient was used. 
The veracity of the observed changes in the 
parameters, caused by experimental drugs, both 
as absolute and in percentage of the initial level 
as well, was find out with the help of the 
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residual method of the variable statistics by 
finding the mean weight of the shifts (M); the 
arithmetic mean (+ m) and the probable error of 
the mean (P) according to Student tables. 
Differences were estimated as significant, 
starting from p <0.05. For calculations, we used 
the program for statistical analysis Microsoft 
Excel 7.0. 
 
Discussion and Results of the Research 
Investigation of the anti-inflammatory 
effect of inhibitors of HMG-CoA reductase 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin on the model 
of formalin edema of mice foot and 
exudative model of inflammation in rabbits 
according to Oivin.  
The use of inhibitors of HMG-CoA 
reductase simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin causes a 
dose-dependent antiexudative effect, appeared 
in decreasing of the gain of weight degree of 
the foot comparing to intact animals (Figure 2).  
The calculated coefficient of inhibitory 
effect (CIE) with an increase in the dose of 
simvastatin from 9 to 35 mg/kg had been 
increasing from 12.7 + 4.6 to 46.3 + 4.9 cu. (p 
<0.05). For atorvastatin, the initial effective 
anti-inflammatory dose was the less and 
amounted to 5 mg/kg for CIE 23.3 + 4.5 cu. 
With dose increasing up to 19 mg/kg, CIE 
became 39.7 + 4.5 cu. Rosuvastatin on this 
exudative inflammation model also 
demonstrated a dose-dependent effect which 
can be compared with The most evident 
antiexudative effect was seen in using of 
nanoparticulated rosuvastatin in the dose range 
of 4 times lower than rosuvastatin (Figure 2). 
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Fig. 2. The anti-inflammatory effect of inhibitors of HMG-CoA-reductase of simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin on the model of formalin edema of the foot of mice 
 
The study results of the anti-inflammatory 
drugs activity according to the E.A. Oivin 
method are shown in Figure 3. 
The study results of the anti-inflammatory 
drugs activity according to the E.A. Oivin 
method are shown in Figure 3. 
Simvastatin in doses of 4.3 and 8.5 mg/kg 
had a dose-dependent anti-inflammatory effect, 
so the result of this was a decreasing of spots 
area to 3.5 ± 0.3 and 3.1 ± 0.3 cm2; and same 
time an increasing the time of its coming out to 
397.1 ± 12, 3 and 397.1 ± 12.3 seconds. In 
comparison with the control values, 5.4 ± 0.3 
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cm
2
 and 236.1 ± 6.4 seconds. Atorvastatin, as 
well as in experiments on mice, started to show 
an anti-inflammatory effect at a lower dose of 
1.1 mg/kg and exerted  more evident  effect, 
reaching its  maximum at 4.3 mg/kg. 
Rosuvastatin turned out to be the most effective 
at doses of 2.2, 4.3 and 8.5 mg/kg, retarding the 
time of spots coming out up to 501.9 ± 21.7, 
531.5 ± 13.8 and 601.7 ± 13, 6 seconds 
compared with the control numbers of  
236.1 ± 6.4 seconds. 
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Fig. 3. Anti-inflammatory effect of inhibitors of HMG-CoA-reductase simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin on the model of anti-exudative action in rabbits 
 
The size of the spots was also minimal and 
amounted to a larger dose of 1.5 ± 0.2 cm2. 
Nanoparticulated rosuvastatin (0.73, 1.43 and 
2.83 mg/kg) showed comparable efficacy with 
a dosage of rosuvastatin base substance 4 times 
exceeding that of nanoparticulated form.  
Thus, statins demonstrate a dose-dependent 
anti-inflammatory (on the model of formalin 
edema of the foot in mice) and anti-exudative 
effect (on the model of exudative inflammation 
in rabbits according to Oivin's method). The 
highest activity was evident in nanoparticulated 
rosuvastatin in the dose range (0.73, 1.43 and 
2.83 mg/kg), which is 4 times lower than in the 
experiments with the base substance (Figure 3). 
The investigation of the cardioprotective 
effect of inhibitors of HMG-CoA-reductase 
of simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin in the 
simulation model of coronary-occlusive 
myocardial infarction in rats. 
The application of the ligature to the 
descending branch of the left coronary artery in 
rats in the control group of animals led to 
myocardial necrosis, the size of which was 
12.71 ± 0.59% of the total myocardium size 
(Figure 4).  
The use of inhibitors of HMG-CoA 
reductase simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin had a dose-
dependent cardioprotective effect. In this 
instance, the statins   we were studying 
appeared to be approximately equally effective 
(Figure 4). 
The blockade of K + -ATPase channels by 
glibenclamide (5 mg/kg) completely stopted the 
cardioprotective effect of inhibitors of HMG-
CoA reductase simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin 
in the simulation model of coronary-occlusive 
infarction in rats (Figure 4). The use of 
aminoguanidine (40 mg/kg) for iNOS blockade 
had also completely stopted the 
cardioprotective effect of the statins which 
were studied (Figure 4). This indicates the 
participation of the effects of mechanisms for 
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the realization of pharmacological 
preconditioning as the "first window" 
(blockade of K + -ATPase channels with 
glibenclamide (5 mg/kg) and the "second 
window" (iNOS blockade with aminoguanidine 
40 mg/kg). 
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Fig. 4. Cardioprotective effect of inhibitors of HMG-CoA reductase simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin on the model of coronary-occlusive infarction in rats 
  
Thereby, the written above indicates that 
statins have a dose-dependent cardioprotective 
effect in the simulation model of coronary-
occlusive infarction in rats.  In cardioprotective 
effects actualization, the mechanisms of 
pharmacological preconditioning are of 
considerable importance, as it became evident 
with   remove of effects during blockade of K + 
-ATPase-channels with glibenclamide and 
blockade of iNOS with aminoguanidine.  
The investigation of endothelioprotective 
effects of inhibitors of HMG-CoA reductase 
of simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin in the 
simulation model of endotoxin-induced 
endothelial dysfunction. 
The simulation model of endotoxin-
induced endothelial dysfunction in 
experimental animals 
When a model of endotoxin-induced 
endothelial dysfunction was created, rats were 
infected with Staphylococcus aureus (strain 
13407), subcutaneously with 60 billion 
microbial bodies, followed by (after 24 hours) 
sensitization of the laboratory animal (0.1 ml of 
staphylococcal anatoxin subcutaneously), after 
that generalization of the infectious agent by 
means of a daily massage at the injection place 
was made. A way of a chronic septic process in 
laboratory animals RU 2143749 C1 6 G09B23 
/ 28 [86] learning.  This model allows having a 
long-term dynamic process of endotoxin 
intoxication with 100% survival of 
experimental animals learning. 
The temperature of the rats body during the 
learning period  was higher than the intact 
group for 2-3 ° C, reaching the maximum 
increase by the sixth day of the experiment  
(40.1 ± 0.2 ° C) and decreasing to the initial 
values by the 15th days of the experiment (38.2 
± 0.1 оС).  This fact demonstrates the dynamics 
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of the generalized sluggish inflammatory 
process, subsiding by itself to this date.  
During the EIED technique working out, 
we paid special attention to the dynamics of the 
coefficient of endothelial dysfunction (CED) as 
an integral indicator characterizing the 
development of pathology. For this purpose, 
experiments were performed on endothelium-
dependent (acetylcholine 40 μg/kg) and 
endothelium-independent (nitroprusside  
30 μg/kg); vascular relaxation in animals with 
EIED on the 3rd, 6th, 9th, 12th and 15th days 
with the subsequent calculation of CED.  
It was discovered that EIED affects the 
functioning of the endothelium, in particular, 
the endothelium-dependent vasodilatation 
caused by acetylcholine. On the third day CED 
was 1.1 ± 0.1, which did not differ from the 
parameter in the control group – 1.1 ± 0.2, and 
can be explained by activation of 
microorganisms and macrophages with 
inducible NOS with a sufficiently intensive 
formation of nitric oxide in the initial period 
septic process.  Hereinafter, by the sixth day of 
the experiment, the endothelial dysfunction rate 
significantly has increased in comparison with 
intact and was 2.1 ± 0.3. In some animals, the 
values reached 5 and even 6. Further, a gradual 
decrease in the coefficient of endothelial 
dysfunction was observed: on the 9th day, 1.8 ± 
0.4, 12 -1.8 ± 0.5, and finally on the 15th day 
the value of CED was coming to the level of 
animals without any pathology –  
1, 3 ± 0. 1. 
According to the given results, for further 
experiments, we performed functional tests on 
the 7th day after the EIED simulation. 
Comparing to intact animals, on the 7th day 
after the simulation EIED had a negative effect 
on the rats on the indicators of central 
hemodynamics and showed a statistically 
significant decrease in SBP and DBP.  
Simultaneously, when the endothelium-
dependent (acetylcholine) and endoterium-
independent (nitroprusside) relaxation tests had 
been done, the CED was increased to 3.7 ± 0.5, 
which is 3 times higher than in intact animals 
(Table 2). 
Table 2 
Changes in hemodynamic parameters in animals with endotoxin-induced endothelial 
dysfunction (M ± m, n = 10) 
 
Group 
Systolic blood 
pressure 
Diastolic blood 
pressure 
Coefficient of 
endothelial 
dysfunction (CED) 
Intact 129.4±2.2 89.2± 1.1 1.1 ± 0.1 
Endotoxin-induced endothelial 
dysfunction 
117.6±2.3* 85.0±2.1* 3.7±0.5* 
Note: SBP – systolic blood pressure (mmHg), DBP – diastolic arterial pressure (mmHg), CED – 
coefficient of endothelial dysfunction (unit units), * – significant difference with a group of intact 
animals (p <0.05). 
 
Adrenoreactivity in animals with EIED 
was 20% higher, and the myocardial reserve 
was 30% lower than in intact animals. 
Analyzing the values of biochemical 
markers, reflecting the metabolism of nitric 
oxide, C-reactive protein and pro-inflammatory 
cytokines the most significant changes has been 
found. Thus, the total content of final 
metabolites of NO (Total NO) in animals with 
EIDD from 116.8 ± 10.3 to 182.3 ± 12.4 μmol/l 
were highly increased. In contrast, eNOS 
expression has been decreasing significantly. 
This fact may indicate a more significant 
contribution of the inducible isoform of the 
enzyme activation (iNOS) to an enlargement of 
NO content. Integral marker of inflammatory 
processes in the vascular wall C-reactive 
protein (CRP) has been increasing its level 
more than 7 times, which indicates the 
development of systemic vasculitis. A similar 
dynamics can be observed in the case of the 
inflammatory cytokines IL-6 and TNF, the 
values of which increased 16 and 2 times, 
respectively (Table 3). 
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Table 3 
Changes in the values of biochemical markers (Total NO, Expression of eNOS,  
C-reactive protein, IL-6, TNF-α) in animals with endotoxin-induced endothelial dysfunction 
(EIED) (M ± m, n = 10) 
Groups of animals NOх 
eNOS 
expression 
C-reactive 
protein 
IL-6 TNF-α 
Intact 116.8±10.3 5.4±0.21 0.05±0.01 0.43±0.17 8.4±2.5 
Endotoxin-induced 
endothelial 
dysfunction 
182.3±12.4* 0.04±0.01* 0.38±0.01* 6.87±1.93* 17.8±3.7* 
Note: NOx is the final metabolite of NO (μmol/L); eNOS expression (%); level of CRP-C-reactive protein (mg/l); IL-
6 – interleukin 6 (pg/ml) TNF-α-tumor necrosis factor α (pg/ml), * – significant difference with a group of intact animals (p 
<0.05). 
 
Thereby, the modeling of endotoxin-
induced pathology by the injection of strain 
13407 of Staphylococcus aureus leads to the 
development of endothelial dysfunction with an 
increase of CED 3.7-fold, a decrease in 
myocardial reserve and an augmentation of 
adrenoreactivity, as well as an enlargement of 
stable NO metabolites against an increase in 
inflammatory markers of C-reactive protein and 
pro-inflammatory cytokines IL-6 and TNF-α. 
Decreased expression of eNOS indicates a 
preferential involvement of the enzyme form 
iNOS in this process.  
The endothelioprotective effects of the 
inhibitors of HMG-CoA-reductase of 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin investigation 
in modeling endotoxin-induced endothelial 
dysfunction.  
The use of inhibitors of HMG-CoA 
reductase of simvastatin, atorvastatin, 
rosuvastatin, and nanoparticulated rosuvastatin 
in EIED modeling revealed an evident dose-
dependent endothelioprotective effect, 
manifested in a significant decrease in CED, 
against normalization of systolic and diastolic 
blood pressure values. Thus, in the simulation 
of EIED, CED was 3.7 ± 0.5, whereas in large 
doses of simvastatin (8.5 mg/kg), atorvastatin 
(4.3 mg/kg), rosuvastatin (8.5 mg/kg) and 
nanoparticulated rosuvastatin (11.6 mg/kg), 
respectively, 2.3±0.5, 2.1±0.3, 1.7±0.5 and 1.5 
± 0.2 c.u., which was close to the values in 
intact animals (1.1±0.1). Wherein, the most 
effective drugs rosuvastatin and its 
nanoparticulated form were (Figure 5). 
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Fig.  5. Indices of endothelial dysfunction coefficient (CED) with the use of inhibitors  
of HMG-CoA reductase simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin  
on the background of endotoxin-induced endothelial dysfunction modeling 
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Parallel to this, conducting stress tests in 
animals with EIED indices a positive dynamics 
of contractility was observed. As a result, the 
prevention of an increase in adrenoreactivity 
and a decrease in the myocardial reserve was 
revealed. At the same time, as in the case of 
CED, rosuvastatin (8.5 mg/kg) and its 
nanoparticulated form (11.6 mg/kg) proved to 
be the most effective. The most evident 
endothelial and cardioprotective effect of 
inhibitors of HMG-CoA reductase of 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin was found out in 
the values of biochemical markers in animals 
with EIED (Figure 6). 
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Fig.  6. Adrenoreactivity indicators with the use of inhibitors of HMG-CoA reductase simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of modeling  
endotoxin-induced endothelial dysfunction 
 
 
The level of final metabolites of NOx and 
eNOS expression, subject to a high increase 
(NOx) (Figure 7) and decrease (Expression of 
eNOS) (Figure 8) in the simulating of 
endotoxin-induced pathology at the effect of 
statins were normalized on the 8th day and  
reached values not differing from intact 
animals at the maximum doses of HMG-CoA 
reductase. It should be noticed that the greatest 
effect the nanoparticulated form of rosuvastatin 
had. This fact supports the hypothesis of a 
change in the volume of distribution of 
rosuvastatin by the blood stream  restriction 
(Figure 9). 
Systemic inflammatory reaction marker the 
C-reactive protein  has showed a 7.5-fold 
increase in EIED, but being under the influence 
of medium and large doses of inhibitors of 
HMG-CoA reductase simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin, 
it  was reduced to values statistically not 
different from intact animals (Figure 9). 
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Fig. 7. Concentration of nitrogen oxide metabolites (NOx) using the inhibitors of HMG-CoA reductase 
simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of 
endotoxin-induced endothelial dysfunction modeling. 
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Fig.  8. Expression of NO-synthase (eNOS) using inhibitors of HMG-CoA reductase simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated rosuvastatin against the background of endotoxin-
induced endothelial dysfunction modeling 
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Fig. 9. C-reactive protein (CRP) indices with the use of inhibitors of HMG-CoA reductase simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background  
of endotoxin-induced endothelial dysfunction modeling 
 
The proinflammatory cytokines IL-6 and 
TNF-α, during the EIED simulating, had 
increased 15 and 2.1 times. The use of medium 
and large doses of inhibitors of HMG-CoA 
reductase, simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin 
had been exerting an evident normalizing effect 
and their values had been approximating to the 
same values in intact animals (Figure 10).
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Fig.  10. The concentration of proinflammatory cytokines IL-6 and TNF-α with the use of inhibitors of 
HMG-CoA reductase simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the 
background of endotoxin-induced endothelial dysfunction modeling 
 
The most pronounced protective effect was 
provided by the nanoparticulated form of 
rosuvastatin 11.6 mg/kg. 
The modeling of L-NAME-induced 
endothelial dysfunction was accompanied by an 
increase in SBP and DBP, an increase in 
adrenoreactivity, a decrease in the myocardial 
reserve, biochemical analysis showed a 
disturbance in the metabolism of nitric oxide, 
histological findings revealed that modeling L-
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NAME-induced NO deficiency on the 8th day 
resulted in bright pronounced hypertrophy of 
myocardiocytes, and spasm of arterioles. 
Inhibitors of HMG-CoA reductase of 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin effect on the 
model of L-NAME-induced deficiency of nitric 
oxide is shown in Figure 11. 
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Fig. 11. Endothelioprotective effects of HMG-CoA reductase inhibitors simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin in L-NAME-induced endothelial dysfunction. 
Note: BPSyst – systolic blood pressure; BPdiast – diastolic blood pressure; CED – coefficient of 
endothelial dysfunction; NOx is the concentration of the nitrite ion in the plasma; eNOS – expression 
of eNOS; AdR – adrenoreactivity; MR – myocardial reserve; MKD is the myocardiocytes diameter  
(% of the group of intact animals) 
 
HMG-CoA reductase inhibitors 
simvastatin, atorvastatin, rosuvastatin, and 
nanoparticulated rosuvastatin had been causing 
a dose-dependent endothelial and 
cardioprotective effect. The result of it came 
out in decreasing of systolic blood pressure 
values had been reaching to statistically 
significant values and were 167.2 ± 10.1, 140.3 
± 9.6, 132.2 ± 7.7 and 120.1 ± 6.4 mm Hg., but 
as for the controlled group, it was 190.3 ± 6.7 
mm Hg. A similar dynamics was found in the 
evaluation of diastolic blood pressure. At the 
same time, CED dose-dependent had been 
decreasing reliably and under nanoparticulated 
rosuvastatin influence  had been reaching 1.9 ± 
0.6 cu., what was almost corresponded to intact 
animals and was practically 3 times less than in 
control 5.4 ± 0.6 cu.   
In experiments with stress tests, inhibitors 
of HMG-CoA reductase simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin had been also demonstrating 
cardioprotective effects and were preventing 
increasing in adrenoreactivity. Thus, in the 
control with simulating a model of L-NAME-
induced nitric oxide deficiency, the maximum 
intraventricular pressure during the test for 
adrenoreactivity was 247.3 ± 4.8 mm Hg, and 
with rosuvastatin and nanoparticulated 
rosuvastatin correction 187.9 ± 10.2 and  
186.4 ± 10.7 mm Hg. respectively, which is 
significantly less than in the control and close 
to the values in intact animals.  
The cardioprotective effect of inhibitors of 
HMG-CoA reductase of simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin had been also seen in improving 
the indicators contractility during the resistance 
stress test. Thus, the values of intraventricular 
pressure in the control group with L-NAME-
induced pathology were 66.0 ± 4.6% on 25th 
second of the test, whereas in the experimental 
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groups with simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin, 
respectively, they were 88.1 ± 5.8; 91.7 ± 6.3; 
92.4 ± 6.7 and 93.5 ± 7.4%, which is 
significantly higher than in the control and does 
not differ from the values in intact animals of 
83.6 ± 4.3%.   
Inhibitors of HMG-CoA reductase 
simvastatin, atorvastatin, rosuvastatin, and 
nanoparticulated rosuvastatin had been causing 
a dose-dependent endothelioprotective effect, 
which was consisted in preventing the increase 
in the values of the final metabolites of NOx 
and reducing eNOS expression. Wherein 
rosuvastatin and its nanoparticulated form had 
the most significant effect.   
So, the use of inhibitors of HMG-CoA 
reductase in simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin  
during simulating a model of  EIED  
(introduction of Staphylococcus aureus strain 
13407), and  in simulating a model of ADMA-
like L-NAME-induced deficiency of NO leads 
to  a dose-dependent endothelioprotective 
effect development, which consists in CED 
normalization, adrenoreactivity encreasing 
prevention and  the myocardial reserve 
depletion as well, and at the same time it leads 
to biochemical markers of inflammation  
(C-reactive protein)  and the level 
proinflammatory cytokines normalization. 
During the experiment positive dynamics of the 
final products of NO and eNOS expression was 
found. At the same time, the values of AD 
significantly were decreasing, and in the 
experiments with nanoparticulated rosuvastatin 
they had reached the set values. 
Investigation of the effect of 
monotherapy with NO donor L-arginine, a 
nonselective inhibitor of arginase-S- (2-boro-
ethyl) -L-cysteine (BEC), a selective 
inhibitor of arginase-2 arginasine and 
darbepoetin in endotoxin-induced 
endothelial dysfunction in experimental 
animals. 
Monotherapy with donator NO L-arginine 
in the dose range of 70, 200 mg/kg daily 
intragastric on the background of the EIDE 
modeling normalized CED and did not 
significantly affect the blood pressure 
indicators. Inhibitors of arginase BEC (5 and 
10 mg/kg) and arginasine (1 and 3 mg/kg) also 
normalized CED and did not affect BP. The 
greatest effect was provided by recombinant 
erythropoietin at a dose of 500 μg/kg. So CED 
was 1.9 ± 0.2 USD, while in the group with 
EIED 3.7 ± 0.5 c. u. (Table 4). 
Table 4  
Effect of monotherapy with L-arginine, BEC, arginasine and darbepoetin on the dynamics  
of hemodynamic parameters in animals with endotoxin-induced endothelial dysfunction (EIED) 
(M ± m, n = 10) 
Group SBP DBP CED 
Intact 129.4±2.2 89.2± 1.1 1.1 ± 0.1 
EIED   117.6±2.3* 85.0±2.1 3.7±0.5* 
EIED + L-arginine 70 mg/kg 
EIED  + 200 mg/kg 
121.9±3.2 
118.5±2.1 
80.7±2.0 
76.3±2.1 
3.1±0.4* 
2.1±0.3*# 
EIED + BEC 5 mg/kg 
EIED +  BEC 10 mg/kg 
114.1±3.0* 
120.5±2.7 
83.5±2.0 
85.7±2.3 
2.9±0.4* 
2.2±0.3*# 
EIED + Arginasine 1 mg/kg 
EIED  + Arginasine 3 mg/kg 
117.8±3.2* 
126.2±3.4 
88.2±2.7 
85.1±2.1 
3.0±0.3* 
2.1±0.3*# 
EIED + Darbepoetin 50 µg/kg 
EIED + Darbepoetin 500 µg/kg 
121.2±3.1 
126.3±3.2 
86.9±2.1 
83.4±2.3 
2.5±0.3* 
1.9±0.2*# 
Note: SBP – systolic blood pressure (mmHg), DBP – diastolic arterial pressure (mmHg), CED – 
coefficient of endothelial dysfunction (unit units), * – significant difference with a group of intact 
animals (p <0.05); # – significant difference with the endotoxin-induced endothelial dysfunction 
(EIED) group (p <0.05). 
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The positive dynamics of the indices of 
contractility in carrying out stress tests in 
animals with EIDD was found in parallel. Thus, 
prevention of an increase in adrenoreactivity 
and a decrease in the myocardial reserve was 
revealed. At the same time, as in CED, arginine 
(3 mg/kg) and darbepoetin (500 μg/kg) were 
the most effective. 
The most pronounced endothelial and 
cardioprotective effect of monotherapy with L-
arginine, BEC, arginine and darbepoetin was 
manifested in the values of biochemical 
markers in animals with EIDD. Thus, under the 
influence of monotherapy with L-arginine, 
BEC, arginasine and darbepoetin, the level of 
final metabolites of NOx in the modeling of 
sepsis increased significantly less than in 
control experiments, and in large doses did not 
differ from intact animals. Similarly, 
monotherapy with these drugs prevented the 
decrease of eNOS expression. The most 
significantly protective effect of monotherapy 
with L-arginine, BEC, arginasine and 
darbepoetin was manifested in relation to the 
level of C-reactive protein and the values of 
proinflammatory cytokines IL-6 and TNF-α 
(Table 5). 
Table 5  
Effect of monotherapy with L-arginine, BEC, arginasine and darbepoetin on the 
dynamics of the values of biochemical markers (total NO, eNOS expression, C-reactive protein, 
IL-6, TNF-α) in animals with endotoxin-induced endothelial dysfunction (EIED) (M ± m, n = 10) 
Group NOх еNOS CRP IL-6 TNF-α 
Intact 116.8±10.3 5.4±0.21 0.05±0.01 0.43±0.17  8.42±2.51 
 EIED   182.3±12.4* 0.04±0.01* 0.38±0.01* 6.87±1.93* 17.83±3.79*  
EIED + L-
arginine 
70 mg/kg 
200 mg/kg   
 
165.4±9.7* 
132.7±11.3*# 
 
1.17±0.27* 
2.14±0.22*# 
 
0.13±0.01* 
0.17±0.02*# 
 
 
3.12±1.12* 
2.23±1.67*# 
 
11.13±2.17* 
10.23±2.08*# 
EIED + BEC  
5 mg/kg  
10 mg/kg 
 
167.1±12.4* 
133.7±10.1*# 
 
2.15±0.32* 
3.21±0.75*# 
 
0.12±0.02* 
0.14±0.01*# 
 
3.98±1.23* 
2.37±1.17*# 
 
10.16±2.37* 
9.97±1.36*# 
EIED + 
arginasine 
1 mg/kg 
3 mg/kg 
 
146.0±13.1* 
125.1±97.3*# 
 
2.39±0.74* 
4.16±1.15*# 
 
0.16±0.03* 
0.10±0.02*# 
 
2.24±1.27* 
2.03±0.98*# 
 
12.89±2.06* 
10.54±1.72*# 
EIED + 
darbepoetin 50 
µg/kg 
 500 µg/kg 
 
145.1±11.7* 
122.5±10.5*# 
 
2.75±0.64* 
4.19±0.72*# 
 
0.21±0.02* 
0.17±0.01*# 
 
2.11±1.12* 
1.72±0.97*# 
 
9.58±2.29* 
8.20±2.26*# 
Note: NOx is the final metabolite of NO (μmol/L); eNOS expression (%); level of CRP-C-reactive 
protein (mg/l); IL-6 – interleukin 6 (pg/ml) TNF-α – tumor necrosis factor α (pg/ml), * – significant 
difference with a group of intact animals (p <0.05); # – significant difference with endotoxin-induced 
endothelial dysfunction (EIED) group (p <0.05). 
 
The obtained results allowed to determine 
the choice of doses. L-arginine 200 mg/kg, 
BEC-10 mg/kg, arginine-3 mg/kg and 
darbepoetin 500 μg/kg for studies on the 
effectiveness of combined use with inhibitors 
of HMG-CoA reductase by simvastatin, 
atorvastatin, rosuvastatin and nano-pararticular 
rosuvastatin. 
Thus, the use of monotherapy with a donor 
NO L-arginine, inhibitors of arginase and 
darbepoetin EIED on background modeling by 
introducing strain 13407 Staphylococcus 
aureus exhibits endotelio- and cardioprotective 
action, expressed in preventing increase CED 
adrenoreactivity, conservation and 
normalization of myocardial reserve 
biochemical marker values (Totals NO, 
expression of eNOS, CRP, IL-6, TNF-α). In 
this case, the drugs had a dose-dependent effect 
and were approximately equally effective. 
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Investigation of the effect of combined 
therapy with the L-arginine and inhibitors 
of HMG-CoA reductase by simvastatin, 
atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin in endotoxin-
induced endothelial dysfunction. 
Monotherapy with donator NO L-arginine 
(200 mg/kg) daily intragastric on the 
background of the EIED modeling normalized 
CED and did not significantly affect blood 
pressure (table 4). Inhibitors of HMG-CoA 
reductase, simvastatin (8.5 mg/kg), atorvastatin 
(4.3 mg/kg), rosuvastatin (8.5 mg/kg) and 
nanoparticularized rosuvastatin (11.6 mg/kg) at 
the most effective doses significantly improved 
CED and did not affect blood pressure (Figure 5).   
 
The protective effect of the combined use of L-arginine with HMG-CoA reductase
inhibitors on the model of L-NAME-induced endothelial dysfunction
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Fig. 12. Endothelioprotective effects of combined use of L-arginine with inhibitors  
of HMG-CoA reductase simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin  
in L-NAME-induced endothelial dysfunction 
Note: BPsyst – systolic blood pressure; BPdiast – diastolic blood pressure; CED – coefficient of 
endothelial dysfunction; NOx – concentration of nitrite ions in plasma; eNOS – expression of eNOS; 
ADR – adrenoreactivity; MR – myocardial reserve; DMK is the diameter of myocardiocytes 
 (% of the group of intact animals) 
 
The combined use of L-arginine with 
HMG-CoA reductase inhibitors simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin showed the most pronounced 
endothelioprotective effect, which was 
reflected in the indices of hemodynamic 
parameters of systolic and diastolic blood 
pressure, as well as CED, which in the EIED 
group did not differ statistically from intact 
animals (Figure 13). 
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Fig. 13. The indices of endothelial dysfunction coefficient (CED) and blood pressure (BP) when 
combined use of L-arginine and HMG-CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin on the background of endotoxin-induced endothelial  
dysfunction (EIED) modeling 
 
At the same time, a positive dynamics of 
contractility indices was found in carrying out 
stress tests in animals with EIED. Thus, the 
prevention of an increase in adrenoreactivity 
and a decrease in the myocardial reserve both 
with the use of L-arginine and with its 
combined use of inhibitors of HMG-CoA-
reductase by simvastatin, atorvastatin, 
rosuvastatin and nanoparticularated 
rosuvastatin was detected. At the same time, as 
with СED, the combined use of drugs led to the 
fact that the values did not differ from those of 
intact animals (Figure 14). 
The most significantly protective effect of 
the combined use of the NO L-arginine donor 
with the HMG-CoA reductase inhibitors 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin was manifested 
with respect to the level of C-reactive protein 
and pro-inflammatory cytokines IL-6 and  
TNF-α, the values of which did not differ from 
such in intact animals (Figures 15-17). 
Thus, the use of combined use of L-
arginine with HMG-CoA reductase inhibitors 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin against the 
background of modeling of EIED and  
L-NAME-induced deficiency of NO exhibits 
endothelial and cardioprotective effect, 
manifested in preventing CED, 
adrenoreactivity, preservation of the 
myocardial reserve and normalization of the 
values of biochemical markers (Total NO, 
expression of eNOS, CRP, IL-6, TNF-α). 
Combined therapy was so effective that the 
values obtained with combined therapy did not 
differ from those obtained in intact animals 
(Figure 12). 
 
 Denisiuk T.A. Pharmacotherapeutic strategies for endothelial dysfunction correction with use of 
statines in syndrome of systemic inflammatory response. 
Research Results in Pharmacology. 2017;3(4):35-77. 
56 
 
December. 2017. 3(4). Research Results in Pharmacology rrpharmacology.ru 
0
50
100
150
200
250
232.0*#
204.8*#
201.5
240.3*
211.4*# 222.1*#
201.0*#
221.0*#
193.8*#
219.1*#
196.7*#
* - P<0.05 compared with intact; #- Р<0.05 compared with EIED
EIED + 
L-arginine  
200 mg/kg
+  statins
EIED + 
statins
E
IE
D
+
 
L
-a
r
g
in
in
e
 
2
0
0
 m
g
/
k
g
E
IE
D
In
ta
c
t
Adrenoreactivity (mmhg) 
 
Fig.  14. Adrenoreactivity indicators for combined use of L-arginine and HMG-CoA reductase 
inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin against the 
background of endotoxin-induced endothelial dysfunction modeling 
 
In the experiments with loading tests, the 
combined use of L-arginine with HMG-CoA 
reductase inhibitors simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin 
also shows an additive cardioprotective effect, 
prevention of adrenoreactivity growth and 
depletion of the myocardial reserve. 
A similar additive effect of combined use 
of L-arginine and HMG-CoA reductase 
inhibitors simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin forms, 
interaction with metabolites of nitrogen NOx 
and eNOS expression. 
In parallel with the dynamics of the 
additive effect of combined application of L-
arginine and inhibitors of HMG-CoA 
reductase, simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin, 
a positive additive effect on the reduction of 
hypertrophy of myocardiocytes was found. 
Thus, the use of combined use of L-
arginine with HMG-CoA reductase inhibitors 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin against the 
background of the EIED and L-NAME-induced 
deficiency shows NO endothelial and 
cardioprotective effect, which is manifested in 
preventing СED increase, adrenoreactivity, 
preservation of the myocardial reserve and 
normalization of biochemical markers (Total 
NO, expression of eNOS, CRP, IL-6, TNF-α). 
Combined therapy was so effective that the 
values obtained with combined therapy did not 
differ from those in intact animals. 
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Fig.  15. Nitric oxide concentration (NOx) and NO synthase expression (eNOS) in combined use  
of L-arginine and HMG-CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin in the context of endotoxin-induced endothelial dysfunction modeling 
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Fig. 16. C-reactive protein (CRP) indices with combined use of L-arginine and HMG-CoA reductase 
inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin in the context  
of endotoxin-induced endothelial dysfunction modeling 
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Fig.  17. Concentration of proinflammatory cytokines IL-6 and TNF-α in combined use of L-arginine 
and HMG-CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin on the background of modeling endotoxin-induced endothelial dysfunction (EIED) 
 
Study of the effect of combined therapy 
with a nonselective inhibitor of arginase S-
(2-boro-ethyl)-L-cysteine (BEC), with 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin in endotoxin-
induced endothelial dysfunction model. 
Monotherapy with a nonselective inhibitor 
of arginase S-(2-boro-ethyl)-L-cysteine (BEC) 
daily intragastric moderately normalized CED 
moderately normalized CED and did not 
significantly affect blood pressure (Table 4). 
The CED value was 2.5 ± 0.4 c. u. Inhibitors of 
HMG-CoA reductase, simvastatin (8.5 mg/kg), 
atorvastatin (4.3 mg/kg), rosuvastatin  
(8.5 mg/kg) and nanoparticulated rosuvastatin 
(11.6 mg/kg) at the most effective doses 
significantly improved CED and did not affect 
blood pressure. The CED values were in the 
range 2.3 – 1.5 c. u. 
The combined use of BEC with statins did 
not show an additive effect with respect to 
CED and BP. Values were even slightly higher 
than with statin monotherapy, however, were 
statistically significantly different from intact 
animals (Figure 18). 
Parallel to this, a positive dynamics of 
contractility indices was observed when 
carrying out stress tests in animals with EIED 
(Figure 19). BEC was inferior in activity to 
statins both in terms of preventing an increase 
in adrenoreactivity, and in terms of conserving 
an expansion reserve. The combined use of 
BEC with simvastatin, atorvastatin, 
rosuvastatin, and nano-pararticular rosuvastatin 
did not lead to an additive enhancement of the 
effect, and the values of intraventricular 
pressure when loading tests were close to those 
in the BEC series and inferior to the HMG-
CoA reductase inhibitors. A similar trend has 
been observed with regard to the values of 
biochemical markers in animals with EIED 
(Figures 20-22). 
The most significantly protective effect 
of the combined use of BEC with inhibitors of 
HMG-CoA reductase by simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin was manifested with respect to the 
level of C-reactive protein whose level was 
comparable in all series of experiments. 
(Figure 21). 
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simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin in endotoxin-induced 
endothelial dysfunction model 
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Fig.  19. Adrenoreactivity in the combined use of S- (2-boro-ethyl) -L-cysteine (BEC) and HMG-CoA 
reductase inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin against 
endotoxin-induced endothelial dysfunction modeling 
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Fig. 20. Nitric oxide concentration (NOx) and NO synthase expression (eNOS) when combined with 
the use of S-(2-boro-ethyl)-L-cysteine (BEC) and HMG-CoA reductase inhibitors simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of modeling endotoxin-
induced endothelial dysfunction 
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Fig. 21. C-reactive protein (CRP) indices in the combined use of S-(2-boro-ethyl)-L-cysteine (BEC) 
and HMG-CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin against endotoxin- induced endothelial dysfunction 
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Fig.  22. Concentration of proinflammatory cytokines IL-6 and TNF-α when combined use  
of S- (2-boro-ethyl) -L-cysteine (BEC) and inhibitors of HMG-CoA reductase of simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of modeling endotoxin-
induced endothelial dysfunction (EIED) 
 
Fig. 23. Protective effect of the combined use of S- (2-boro-ethyl) -L-cysteine (BEC) with HMG-CoA 
reductase inhibitors on the model of L-NAME-induced endothelial dysfunction 
Note: BPSyst – systolic blood pressure; BPdiast – diastolic blood pressure; CED – coefficient of 
endothelial dysfunction; NOx – concentration of nitrite ions in plasma; eNOS – expression of eNOS; 
ADR – adrenoreactivity; MR – myocardial reserve; DMK is the diameter of myocardiocytes  
(% of the group of intact animals) 
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The effect of combined therapy with a non-
selective inhibitor of arginase BEC (10 mg/kg) 
with inhibitors of HMG-CoA reductase by 
simvastatin (8.5 mg/kg), atorvastatin  
(4.3 mg/kg), rosuvastatin (8.5 mg/kg) and 
nanoparticulated rosuvastatin (11.6 mg/kg) on 
the model of L-NAME-induced deficiency of 
nitric oxide is shown in Figure 23. 
BEC moderately reduced systolic and 
diastolic blood pressure and 2-fold decreased 
CED, the value of which was 2.5 ± 0.5 c.u., 
whereas in control 5.4 ± 0.6 c.u. (table 4). 
HMG-CoA reductase inhibitors simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin caused more pronounced 
endothelial and cardioprotective effects in 
preventing the increase in blood pressure and 
CED (Figure 5). 
The combined use of a nonselective 
inhibitor of BEC arginase with simvastatin, 
atorvastatin, rosuvastatin, and nanoparticulated 
rosuvastatin also had a protective effect, but did 
not show an additive effect. In the experiments 
with loading tests, the combined use of BEC 
with HMG-CoA reductase inhibitors also 
revealed a cardioprotective effect, preventing 
an increase in adrenoreactivity and depletion of 
the myocardial reserve. At the same time, the 
combined use of drugs did not increase the 
cardioprotective effect, and the adrenoreactivity 
values even increased slightly compared to 
statin monotherapy. A similar additive effect of 
the combined use of BEC and inhibitors of 
HMG-CoA-reductase of simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin was also observed with respect to 
the values of the final NOx metabolites and 
eNOS expression. In parallel with the dynamics 
of the cardioprotective effect of the combined 
use of BEC with HMG-CoA reductase 
inhibitors, a positive effect has been found with 
respect to the reduction of hypertrophy of 
myocardiocytes. 
Thus, the use of the combined use of a 
nonselective inhibitor of arginase BEC with 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin against the 
background of endotoxin-induced pathology 
modeling, and L-NAME-induced NO 
deficiency, exhibits endothelial and 
cardioprotective effects in preventing CED, 
adrenoreactivity, preservation of the 
myocardial reserve and normalization of the 
values of biochemical markers (Total NO, 
eNOS expression, C-reactive protein, IL-6, 
TNF-α). At the same time, combined therapy 
showed no additive effect of drugs (Figure 23). 
Study of the effect of combined therapy 
with a selective inhibitor of arginase-2 
arginasine with simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated 
rosuvastatin in endotoxin-induced 
endothelial dysfunction. 
Monotherapy with a selective inhibitor of 
arginase-2 arginasine (3 mg/kg) daily 
intragastric on the background of modeling 
EIED moderately normalized CED and did not 
significantly affect blood pressure (Figure 19). 
The average value of CED was 2.1 ± 0.3 cu. 
Inhibitors of HMG-CoA reductase, simvastatin 
(8.5 mg/kg), atorvastatin (4.3 mg/kg), 
rosuvastatin (8.5 mg/kg) and nanoparticularized 
rosuvastatin (11.6 mg/kg) at the most effective 
doses significantly improved CED and did not 
affect blood pressure. The CED values were in 
the range 2.3 – 1.5 cu. 
The combined use of a selective inhibitor 
of arginase-2 arginasine (3 mg/kg) with statins 
showed the additivity of the effect against CED 
and BP. Values were even slightly higher than 
with monotherapy with statins, however, were 
statistically significantly different from intact 
animals (Figure 24). In parallel, a positive 
dynamics of contractility indices was found in 
carrying out stress tests in animals with 
endotoxin-induced endothelial dysfunction. 
The selective inhibitor of arginase-2 arginasine 
(3 mg/kg) was superior to statins both in terms 
of preventing an increase in adrenoreactivity 
and in terms of conserving an expansion 
reserve. The combined use of arginasine with 
simvastatin, atorvastatin, rosuvastatin, and 
nanoparticulated rosuvastatin resulted in an 
additive enhancement (Figure 25). 
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Fig.  24. Indices of endothelial dysfunction coefficient (CED) and arterial pressure (BP) when 
combined use of arginasine and HMG-CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin on the background of endotoxin-induced endothelial dysfunction 
(EIED) modeling 
 
A similar trend has been observed with 
respect to the values of biochemical markers in 
animals with endotoxin-induced endothelial 
dysfunction (Fig. 26). 
The most significantly protective effect of 
the combined use of a selective inhibitor of 
arginase-2 arginasine (3 mg/kg) with inhibitors of 
HMG-CoA reductase by simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin was manifested in relation to the 
level of C-reactive protein and the values of 
proinflammatory cytokines IL-6 and TNF- α, the 
levels of which were comparable in all series of 
experiments that received pharmacotherapy 
(Figures 27, 28). We did not find an additive 
effect when combined in this model of pathology. 
In the model of L-NAME-induced nitric 
oxide deficiency, arginine (3 mg/kg) 
moderately reduced systolic and diastolic blood 
pressure and reduced CED by a factor of 1.7 ± 
0.6, while in control 5.4 ± 0,6 c.u. Inhibitors of 
HMG-CoA reductase simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin 
caused more pronounced endothelial and 
cardioprotective effects in preventing the 
increase in blood pressure and CED. 
The combined use of a selective inhibitor 
of arginase-2 arginasine (3 mg/kg) with 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin also had a 
protective effect and showed an additive effect, 
manifested in a decrease in the endothelial 
dysfunction coefficient, prevention of NOx 
concentration decrease, and improvement of 
indices myocardial contractility in conducting 
functional tests for adrenoreactivity and 
resistance loading, reduction of hypertrophy of 
myocardiocytes (Figure 29).
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Fig. 25. Adrenoreactivity in the combined use of arginasine and HMG-CoA reductase inhibitors 
simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin in the context of modeling 
endotoxin-induced endothelial dysfunction (EIED) 
* - P<0.05 compared with intact; #- Р<0.05 compared with EIED
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Fig. 26. Nitric oxide concentration (NOx) and NO synthase expression (eNOS) combined with the use 
of arginasine and HMG-CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin on the background of modeling endotoxin-induced endothelial 
dysfunction (EIED) 
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Fig. 27. Concentration of C-reactive protein (CRP) with the combined use of arginasine and HMG-
CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin in 
the context of endotoxin-induced endothelial dysfunction (EIED) modeling 
* - P<0.05 compared with intact; #- Р<0.05 compared with EIED
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Fig.  28. Concentration of IL-6 TNF-α with the combined use of arginasine and HMG-CoA reductase 
inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin in the context of 
modeling endotoxin-induced endothelial dysfunction (EIED) 
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Fig.  29. Protective action of combined arginine with HMG-CoA reductase inhibitors  
on the model of L-NAME-induced endothelial dysfunction 
Note: BPsyst – systolic blood pressure; BPdiast – diastolic blood pressure; CED – coefficient of 
endothelial dysfunction; NOx – concentration of nitrite ions in plasma; eNOS – expression of eNOS; 
ADR – adrenoreactivity; MR – myocardial reserve; DMK is the diameter of myocardiocytes 
(% of the group of intact animals) 
 
 
Thus, the use of the combined use of a 
selective inhibitor of arginase-2 arginasine (3 
mg/kg) with simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin 
against endotoxin-induced pathology modeling, 
and L-NAME-induced NO deficiency, exhibits 
ectothelial and cardioprotective effects, 
expressed in preventing the increase in CED, 
adrenoreactivity, preservation of the 
myocardial reserve and normalization of the 
values of biochemical markers (Total NO, 
eNOS Expression, C-reactive protein, IL-6, 
TNF-α). At the same time, combined therapy 
revealed the additive effect of drugs. 
Study of the effect of combined therapy 
with darbepoetin, simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin 
in endotoxin-induced endothelial dysfunction. 
The combined use of darbepoetin  
(500 μg/kg) with statins showed additivity of 
the effect against СED and BP. Values were 
even slightly higher than with statin 
monotherapy, however, were statistically 
significantly different from intact animals  
(Figure 30). 
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Fig.  30. The indices of endothelial dysfunction coefficient (CED) with the combined use of 
darbepoetin and HMG-CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin in the context of modeling endotoxin-induced endothelial  
dysfunction (EIED) 
 
The most significantly protective effect of 
the combined use of darbepoetin (500 μg/kg) 
with inhibitors of HMG-CoA reductase by 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin was manifested 
in relation to the level of C-reactive protein and 
the values of proinflammatory cytokines IL-6 
and TNF- were comparable in all series of 
experiments that received pharmacotherapy. 
We did not find the additive effect of combined 
use on this model of pathology (Figures 31-33).  
Thus, the use of the combined use of 
darbepoetin (500 μg/kg) with simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin against the background of 
endotoxin-induced pathology modeling, the 
introduction of strain 13407 of Staphylococcus 
aureus shows endothelial and cardioprotective 
effects, which is manifested in preventing CED 
and adrenoreactivity, preservation of the 
myocardial reserve and normalization of the 
values of biochemical markers (Total NO, 
eNOS expression, C-reactive protein, IL-6, 
TNF-α). At the same time, combined therapy 
revealed the additive effect of drugs  
(Figures 31-33). 
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Fig. 31. Nitric oxide (NOx) concentration and NO-synthase (eNOS) expression in combined use of 
darbepoetin and HMG-CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin against endotoxin-induced endothelial dysfunction (EIED) modeling 
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Fig. 32. Concentration of C-reactive protein (CRP) in the combined use of darbepoetin and HMG-CoA 
reductase inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin in the 
context of modeling endotoxin-induced endothelial dysfunction (EIED) 
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Fig. 33. Concentration of IL-6 and TNF-α with the combined use of darbepoetin and HMG-CoA 
reductase inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin in the 
context of modeling endotoxin-induced endothelial dysfunction (EIED) 
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In the model of L-NAME-induced 
deficiency of nitric oxide, darbepoetin (500 
μg/kg) moderately reduced systolic and 
diastolic blood pressure and reduced CED by a 
factor of 1.8, with a value of 1.8 ± 0.3, whereas 
in control 5.4 ± 0.6 c.u. Inhibitors of HMG-
CoA reductase simvastatin, atorvastatin, 
rosuvastatin, and nanoparticulated rosuvastatin 
caused a more pronounced endothelial and 
cardioprotective effect in preventing the 
increase in blood pressure and CED (Figure 
34). 
The combined use of darbepoetin (500 
μg/kg) with simvastatin, atorvastatin, 
rosuvastatin, and nanoparticulated rosuvastatin 
also had a protective effect and showed an 
additive effect (Figure 28), expressed in a 
decrease in the endothelial dysfunction 
coefficient, prevention of NOx concentration 
increase, and improvement in myocardial 
contractility when conducting functional tests 
for adrenoreactivity and resistance load; 
reduction of hypertrophy of myocardiocytes. 
Further analysis of combinations of 
inhibitors of HMG-CoA reductase and 
endothelioprotectors was carried out on the 
basis of the resulting areas obtained as a result 
of integral vector analysis, the values of which 
are presented in Table 6. Comparing the areas 
of vector diagrams, we obtained distinct 
differences between the group of intact 
animals, animals with endotoxin-induced 
endothelial dysfunction modeling and groups of 
animals with pharmacological correction of the 
above preparations. 
Further, a probabilistic percentage of the 
additions (Padd) of the tested combinations 
(Table 6) was determined using an integral 
vector analysis of combinations of HMG-CoA 
reductase inhibitors and endothelioprotectors. 
The highest probability percentage of the 
additive for simvastatin was in combination 
with the selective inhibitor of arginase-2 with 
arginine – 21.0 ± 1.9%. Similarly, atorvastatin 
worked at 22.6 ± 2.1%. It is noteworthy that the 
maximum values of the additive effect were 
found for combinations of rosuvastatin with 
arginine (3 mg/kg) and darbepoetin (500 
μg/kg), respectively, 31.9 ± 2.8 and 30.2 ± 
2.9%. Nanoparticulated rosuvastatin also 
showed the greatest addiction with arginasine 
and darbepoetin 30.2 ± 2.9 and 26.0 ± 2.7%, 
respectively (Table 6). 
Table 6  
Probabilistic percent of additions (Padd) of the studied combinations in the modeling of ED 
 
Experimental group Padd (%) 
ED + L-arginine 200 mg/kg + Simvastatin 8,5 mg/kg 
ED + BEC 10 mg/kg + Simvastatin 8,5 mg/kg 
ED + Arginasine 3 mg/kg + Simvastatin 8,5 mg/kg 
ED + Darbepoetin 500 µg/kg + Simvastatin 8,5 mg/kg 
3.4±0.3 
-0.01±0.1 
21±1.9# 
9.2±1.1# 
ED + L-arginine 200 mg/kg + Atorvastatin 4,3 mg/kg 
ED + BEC 10 mg/kg + Atorvastatin 4,3 mg/kg 
ED + Arginasine 3 mg/kg + Atorvastatin 4,3 mg/kg 
ED + Darbepoetin 500 µg/kg + Atorvastatin 4,3 mg/kg 
14.2±1.7# 
0.0±0.1 
22.6±2.1# 
13.4±1.8# 
ED + L-arginine 200 mg/kg +Rosuvastatin 8,5 mg/kg  
ED + BEC 10 mg/kg + Rosuvastatin 8,5 mg/kg  
ED + Arginasine 3 mg/kg + Rosuvastatin 8,5 mg/kg 
ED + Darbepoetin 500 µg/kg + Rosuvastatin 8,5 mg/kg 
23.5±2.7# 
0.01±0.1 
31.9±2.8# 
30.2±2.9# 
ED + L-arginine 200 mg/kg Nanorosuvastatin 11,6 mg/kg 
ED + BEC 10 mg/kg + Nanorosuvastatin 11,6 mg/kg 
ED + Arginasine 3 mg/kg +Nanorosuvastatin 11,6 mg/kg 
ED + Darbepoetin 500 µg/kg + Nanorosuvastatin 11,6 mg/kg 
21±2.4# 
0.0±0.1 
30.2±2.9# 
26.0±2.7# 
Note: ED – endothelial dysfunction; Padd – probability percentage of additions (%); * – p <0.005 in 
comparison with ED; # – p <0.005 compared with the endothelioprotective agent. 
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Discussion 
The results of this research allow us to 
affirm that simulating a model of endotoxin-
induced pathology created by injecting strain 
13407 Staphylococcus aureus, leads to the 
development of endothelial dysfunction with 
changes in the response to endothelium-
dependent and endothelium-independent 
vascular tests; to increasing of stable NO 
metabolites with inflammatory markers values 
raise: C-reactive protein, IL -6 and TNF-α. So, 
these phenomena correspond to the clinical 
picture of endotoxin-induced multi-organ 
pathology typical for after abdominal disasters 
with the development of systemic vasculitis 
and a further cascade of atherosclerotic changes 
in the vascular bed. The use of inhibitors of 
HMG-CoA reductase of simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin during simulating a model of 
endotoxin-induced pathology leads to a dose-
dependent endothelioprotective effect 
development, which is expressed in CED 
normalization, adrenoreactivity prevention and 
myocardial reserve depletion, as well as to 
normalization of biochemical markers of 
inflammation and level of proinflammatory 
cytokines. The experiment had demonstrated 
positive dynamics of the final products of NO 
and expression of eNOS. It was proved that 
rosuvastatin and its nanoparticulated form had 
the most significant effect.  Statins has both 
anti-inflammatory and cardioprotective effects. 
In the implementation of anti-inflammatory and 
cardioprotective effects, the mechanisms of 
pharmacological preconditioning are of great 
importance.  This fact was proved with effects 
removal in the blockade of К+-АТF-ase 
channels and blockade of iNOS.  
The combined use of L-arginine, a 
nonselective inhibitor of arginase, a selective 
inhibitor of arginase-2, arginasine, and 
recombinant darbepoetin with HMG-CoA 
reductase inhibitors had showed that the drugs 
enhance the endothelioprotective effects of 
each other. The combination of rosuvastatin 
with arginasine and darbepoetin gives the most 
additive effect. A possible explanation of the 
research results can be expressed as the 
analysis of application points of the drugs and 
the suggestion of their pharmacodynamic 
interaction (Figure 35). 
 
 
Fig. 35. Hypothetical ways of pharmacodynamic interaction of HMG-CoA reductase inhibitors, 
erythropoietin preparations and endothelioprotectors 
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By inhibiting the intracellular factors Rac1, 
Ras and Rho, statins reduce the production of 
reactive oxygen species and the production of 
pro-inflammatory cytokines, and same time 
they increase the activity of eNOS.  
Erythropoietin affects mitochondria through the 
secondary mediators by suppressing their 
activity. This also reduces the production of 
free radicals. Endothelioprotectors by 
activating eNOS, increase the correlation of 
eNOS / iNOS, which leads to decreasing of 
nitrosative stress and to improvement of 
endothelial function.  As for a   perspective of  
further  research of this topic the authors 
assume to investigate  therapeutic and 
prophylactic measures in patients with 
endotoxin-induced pathology, including 
peritonitis, abscesses and others purulent-septic 
complications of the abdominal cavity and 
small pelvis, as well as different acute and 
chronic intoxications accompanied by systemic 
vasculitis and endothelial dysfunction with the 
use of HMG-CoA reductase inhibitors and their 
combination with endothelioprotectors of 
various mechanisms of action. 
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